Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 CAR T cells GLPG5101

A preparation of autologous stem-like early memory T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T cells GLPG5101 specifically recognize and kill tumor cells expressing CD19. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-CD19 CAR-T cells GLPG5101
Code name:	19CP 02 19CP-02 19CP02 GLPG 5101 GLPG-5101 GLPG5101

autologous anti-CD19 CAR T cells GLPG5101

Search NCI's Drug Dictionary